Understanding The Connections Between Aboriginal And Torres Strait Islander Culture, Health And Wellbeing To Support Action To Improve Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$1,915,802.00
Summary
Little is known about the inter-relationship of cultural factors and Aboriginal and Torres Strait Islander health outcomes and these relationships have not been quantified. Through a large cohort study, this research will produce data that combines standard health measures with newly developed quantitative measures of cultural factors, supported by data linkage infrastructure. Robust analytical methods will be used to inform policy and program development.
Predicting Renal, Ophthalmic, And Heart Events In The Aboriginal Community – THE PROPHECY Study
Funder
National Health and Medical Research Council
Funding Amount
$2,574,486.00
Summary
Up to 30% of adult Aboriginal people have diabetes yet our knowledge of the causes and predictors of complications remain incomplete. We have established the PROPHECY Study to assess the levels of complications in Aboriginal people with diabetes; to understand the way that these complications occur, and identify what clinical, social and genetic factors could predict who will get those complications to guide clinical management and prevention.
Clinical Review Of A Cohort Aged 22-33 Years Conceived Using Assisted Reproductive Technologies
Funder
National Health and Medical Research Council
Funding Amount
$946,454.00
Summary
In a recent study, using telephone-interviews, we compared the health and wellbeing of 547 singleton young adults born following assisted reproductive technologies (ART), with 549 matched controls. Reviewing their health when they are 22-33 years is possible because of their ongoing interest. We have a protocol in place to measure their cardiac and respiratory function and other aspects of growth and development. Our findings will fill a major knowledge gap about the longer term safety of ART.
Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.